Skip to main content

Table 3 Concomitant antimicrobial therapy in clinically evaluable population

From: Clinical and microbiological efficacy of continuous versus intermittent application of meropenem in critically ill patients: a randomized open-label controlled trial

Parameter Infusion group
(n= 106)
Bolus group
(n= 108)
P- value
Any 51 (48.1%) 55 (50.9%) 0.685
Penicillins 11 (10.4%) 5 (4.6%) 0.126
penicillin G 3 1 0.367
oxacillin 4 2 0.443
piperacillin/tazobactam 4 2 0.443
Aminoglycosides 4 (3.8%) 1 (0.9%) 0.210
Fluoroquinolones 6 (5.7%) 3 (2.8%) 0.330
Vancomycin 4 (3.8%) 11 (10.2%) 0.106
Linezolid 11 (10.4%) 7 (6.5%) 0.335
Metronidazole 7 (6.6%) 13 (12.0%) 0.240
Antifungals 34 (32.1%) 30 (27.6%) 0.551
  1. Values are presented as absolute (percentage).